Form 4: Krystal Biotech Director Dino Rossi Granted 5,000 Stock Options

Krystal Biotech, Inc. Director Dino A. Rossi was granted 5,000 stock options with an exercise price of $137.46, vesting over one year, effective June 30, 2025.

Summary

• Director Dino A. Rossi of Krystal Biotech, Inc. (KRYS) was granted 5,000 stock options.
• The options have an exercise price of $137.46 per share.
• The grant date for these options is June 30, 2025.
• The options will vest in equal monthly tranches over a one-year period starting from the grant date.
• The expiration date for these options is June 30, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive signal, indicating alignment of interests and long-term incentive, though it's a routine compensation event.

Positives

• Grant of 5,000 stock options to a director aligns their interests with shareholder value creation.
• The options have a 10-year expiration period, providing a long-term incentive for the director.

Negatives

• No explicit negative financial or operational information was disclosed.

Risks

• No specific risks related to company operations or financial health were disclosed in this Form 4 filing.

Future Outlook

This Form 4 filing primarily reports an insider transaction and does not contain forward-looking statements or guidance regarding the company's future performance.

Management Comments

• No direct management comments or notable quotes were included.

Industry Context

This Form 4 filing details an individual insider transaction (stock option grant) and does not provide information for broader industry trend analysis or competitor comparison.

Comparison to Industry Standards

• Not applicable; this Form 4 filing reports an individual insider transaction and does not contain information for comparison to industry-wide financial or operational benchmarks.

Management Changes

Corporate Governance

Legal Proceedings

• No legal proceedings or regulatory matters were disclosed.

Related Party Transactions

• The filing reports the grant of stock options to Dino A. Rossi, a director of Krystal Biotech, Inc., as part of his compensation.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aligns management incentives with shareholder value creation, potentially leading to long-term growth.
• Employees: No direct impact on employees is indicated by this specific director's option grant.

Next Steps

• The granted stock options will vest in equal monthly tranches over a one-year period starting June 30, 2025.

Key Dates

Keywords

Krystal Biotech, KRYS, Form 4, stock options, insider transaction, director compensation, equity grant